Blair William & Co. IL Grows Position in Edwards Lifesciences Co. (NYSE:EW)

Blair William & Co. IL grew its position in Edwards Lifesciences Co. (NYSE:EW) by 3.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 924,413 shares of the medical research company’s stock after buying an additional 28,241 shares during the quarter. Blair William & Co. IL owned 0.15% of Edwards Lifesciences worth $95,741,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Miracle Mile Advisors LLC increased its position in shares of Edwards Lifesciences by 9.3% in the second quarter. Miracle Mile Advisors LLC now owns 9,053 shares of the medical research company’s stock valued at $938,000 after buying an additional 767 shares in the last quarter. Sarasin & Partners LLP boosted its stake in shares of Edwards Lifesciences by 25.9% during the second quarter. Sarasin & Partners LLP now owns 254,535 shares of the medical research company’s stock valued at $26,362,000 after acquiring an additional 52,386 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Edwards Lifesciences during the first quarter valued at $48,439,000. Peregrine Capital Management LLC boosted its stake in shares of Edwards Lifesciences by 4.8% during the second quarter. Peregrine Capital Management LLC now owns 447,578 shares of the medical research company’s stock valued at $46,356,000 after acquiring an additional 20,564 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Edwards Lifesciences by 22.4% during the second quarter. BNP Paribas Arbitrage SA now owns 366,508 shares of the medical research company’s stock valued at $37,959,000 after acquiring an additional 67,183 shares during the last quarter. Institutional investors and hedge funds own 80.13% of the company’s stock.

A number of brokerages have issued reports on EW. Oppenheimer raised their price target on Edwards Lifesciences from $97.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, July 30th. Stifel Nicolaus raised their price target on Edwards Lifesciences from $103.00 to $120.00 and gave the stock a “buy” rating in a research note on Friday, July 30th. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $93.00 to $115.00 and gave the company an “equal weight” rating in a research note on Friday, July 30th. Canaccord Genuity lifted their price objective on Edwards Lifesciences from $103.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, July 30th. Finally, Piper Sandler lifted their price objective on Edwards Lifesciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research note on Tuesday, July 27th. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $116.33.

Shares of NYSE:EW traded down $2.35 during midday trading on Monday, reaching $117.72. The company had a trading volume of 10,669 shares, compared to its average volume of 2,454,917. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.75 and a quick ratio of 2.89. The stock’s fifty day moving average price is $115.87 and its 200-day moving average price is $101.49. The stock has a market capitalization of $73.38 billion, a P/E ratio of 51.53, a PEG ratio of 3.40 and a beta of 1.08. Edwards Lifesciences Co. has a one year low of $70.92 and a one year high of $123.27.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 29th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.09. The business had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.29 billion. Edwards Lifesciences had a net margin of 29.69% and a return on equity of 29.73%. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.26 earnings per share for the current year.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 15,000 shares of the business’s stock in a transaction on Monday, August 2nd. The shares were sold at an average price of $113.53, for a total transaction of $1,702,950.00. Following the completion of the sale, the vice president now owns 42,759 shares in the company, valued at $4,854,429.27. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 32,550 shares of the company’s stock in a transaction that occurred on Tuesday, August 3rd. The stock was sold at an average price of $114.14, for a total transaction of $3,715,257.00. Following the completion of the sale, the chief executive officer now directly owns 233,052 shares of the company’s stock, valued at $26,600,555.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 96,530 shares of company stock valued at $11,055,715. Insiders own 1.35% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.

Further Reading: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.